NCT06321536
Response to Emerging Antimicrobial Resistance With Containment Microbiota Therapy (REACT)
At risk: Primary endpoint(s) modified.
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 6 versions: 6 with changes below. See every version on ClinicalTrials.gov ↗
Notable Primary endpoint(s) modified Show 7 more changesShow less
- Eligibility criteria expanded, about 30 words
- Enrollment closed, study ongoing
- Enrollment target: estimated 60 to confirmed 58
- Primary completion date changed from estimate of Jul 2026 to Jul 8, 2026
- Study completion date: Dec 2026 to Jan 2027
- Secondary endpoints revised (3)
- Site details revised at 4 of 4 sites
- Notable Enrollment target: 200 to 60
- Primary completion date: Dec 2025 to Jul 2026
- Study sites: 1 to 4
- Study completion date: Dec 2025 to Dec 2026
Notable Trial status: Not Yet Recruiting to Recruitingv4 Show 4 more changesShow less
- Eligibility criteria shortened, about 4 words
- Start date changed from estimate of Jan 2025 to Jan 13, 2025
- Study description shortened, about 46 words
- Site details revised
- Notable Start date: Oct 2024 to Jan 2025
- Primary and study completion dates: Jun 2025 to Dec 2025
- Notable Start date: May 2024 to Oct 2024v2
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Difference in number of solicited Adverse Events (AEs)
Timeframe: Day 0, Day 7 post-intervention
Difference in severity of solicited AEs
Timeframe: Day 0, Day 7 post-intervention
Difference in number of unsolicited AEs
Timeframe: Day 0, Day 28 post-intervention
Difference in severity of unsolicited AEs
Timeframe: Day 0 and Day 28
Number of participants by composite MDRO Colonization and survival status
Timeframe: Day 28 post-intervention
Secondary (3)
Count of serious AEs (SAEs)
Count of AEs of Special Interest (AESIs)
Number of participants by category-specific MDRO Colonization and survival status
Arms and interventions
Group 1: microbiota therapy (MT)Experimental
Group 1 will offer Microbiome therapeutic (MT) to all MDRO-positive patients (i.e., intervention condition).
Group 2: ObservationNo intervention
Group 2 will be assigned to observation.
Drugs: Allogeneic Microbiota in Glycerol (9%) (AMG)
Sites
4 sites in 1 country